#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pulmonary fibrosis Ocular myasthenia Congenital megacolon Stevens-Johnson syndrome Peripheral primitive neuroectodermal tumour of soft tissue Leukoencephalopathy Antiphospholipid syndrome Hereditary spastic paraplegia Adenoid cystic carcinoma Chronic kidney disease Fibrosarcoma metastatic Multifocal motor neuropathy Cataract Epidermolysis bullosa Primary biliary cholangitis More trials…

    Learn about Rare Diseases

    Lennox-Gastaut syndrome Encephalitis autoimmune – Treatment Mantle cell lymphoma stage III Mastocytosis – Diagnostics Hereditary ataxia – Basic Information Haemophilia B without inhibitors – Life with Disease Systemic sclerosis pulmonary Leukoencephalopathy – Treatment Pleomorphic leiomyosarcoma – Life with Disease Nodal marginal zone B-cell lymphoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    GSKVX000000034796 Allogeneic Faecal Microbiota Other Immunosuppressants Human Coagulation Factor X Deoxyribonucleic Acid Isoflurane Io102 Hydrochloride Nebivolol Mepivacaine Hydrochloride Brivaracetam Balstilimab Riociguat Acoramidis Ag-946 Human Coagulation Factor Viii Sodium Phosphate Oritavancin Resatorvid ALKYLATING AGENTS Pramlintide Acetate More therapies…

    Learn about Your Condition

    Hypereosinophilic syndrome Ovarian cancer metastatic Ophthalmoplegia Tuberous sclerosis complex Thermal burn Anal cancer stage II Retroperitoneal cancer Abdominal infection Mitral valve incompetence Renal cancer Chronic sinusitis Paraganglion neoplasm Biliary tract operation Pruritus Dengue fever More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hospital Santa Caterina Ias

Hospital Santa Caterina Ias

Calle Del Doctor Castany S/N, Salt, 17190, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Investigated Diseases:
    • Primary progressive multiple sclerosis
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • RO7268489
    • Ocrelizumab
    France Germany Hungary Italy Poland Portugal +1

  • Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Relapsing multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    • Remibrutinib
    Belgium Czechia Denmark France Germany Greece +4

  • Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Relapsing-remitting multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    Belgium Bulgaria Croatia Czechia Denmark France +9

  • A study testing aprepitant gel for treating skin rash in cancer patients receiving epidermal growth factor receptor inhibitor therapy

    Not recruiting

    2 1
    Investigated Drugs:
    • Aprepitant
    Hungary Poland Spain

  • Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated Drugs:
    • Tolebrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +13

  • Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis relapse
    Investigated Drugs:
    • A/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type)
    • A/Wisconsin/67/2022 (H1N1)Pdm09-Like Strain (A/Georgia/12/2022 Cvr-167)
    • B/Austria/1359417/2021-Like Strain (B/Singapore/Wuh4618/2021)
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Relapsing multiple sclerosis
    Investigated Drugs:
    • Charcoal, Activated
    • Colestyramine
    • Magnesium Citrate
    Austria Belgium Bulgaria Croatia Denmark Ireland +7

  • Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis relapse
    Investigated Drugs:
    • Diroximel Fumarate
    • Interferon Beta-1A
    • Peginterferon Beta-1A
    France Germany Italy Spain
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!